Preferred Label : Listeria monocytogenes-LLO-Prostate Cancer Neoantigens Vaccine ADXS-504;
NCIt synonyms : Lm-LLO-Prostate Cancer Neoantigens ADXS-504; Lm-LLO-PC Neoantigens Vaccine ADXS-504; Listeria monocytogenes-LLO-PC Neoantigens Vaccine ADXS-504;
NCIt definition : An off-the-shelf (OTS) cancer vaccine containing a live-attenuated strain of the Gram-positive
bacterium Listeria monocytogenes (Lm) encoding a fusion protein composed of specific
prostate cancer (PC) neoantigens fused to a fragment of the immunostimulant listeriolysin
O (LLO) protein, with potential immunostimulatory and antineoplastic activities. Upon
administration of the Lm-LLO-PC neoantigens vaccine ADXS-504, the expressed LLO-PC
neoantigens is processed by antigen presenting cells (APCs), presented to the immune
system by both major histocompatibility complex (MHC) I and II molecules, and activates
the immune system to exert both an innate and adaptive immune response involving the
recruitment and activation of T-lymphocytes against neoantigen-expressing prostate
cancer cells as well as the inhibition of tumor-infiltrating T regulatory cells (T
regs) and myeloid-derived suppressor cells (MDSCs). This further modulates the tumor
microenvironment (TME) and further results in tumor cell eradication. The neoantigens
in ADXS-504 are composed of public hotspot mutations and proprietary tumor associated
antigen (TAAs).;
Molecule name : ADXS 504; ADXS-504;
NCI Metathesaurus CUI : CL1643049;
Origin ID : C177282;
UMLS CUI : C5447674;
Semantic type(s)
- concept_is_in_subset
